BRIEF — Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0% — 73.1% At Week 96
Oct 17 (Reuters) — AbbVie Inc.: Abbvie - Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96 Abbvie - Upadacitinib In Crohn's Disease Shows Clinical Remission Rates Of 78.9%-86.6% At Week 144 Source text:... Further company coverage: ABBV.N (Reuters.Briefs@thomsonreuters.com;)